Literature DB >> 17245403

Cardiac resynchronization therapy or atrio-biventricular pacing-what should it be called?

John G F Cleland1, Mansour Nasir, Ahmed Tageldien.   

Abstract

Reduced cardiac efficiency caused by suboptimal synchronization of the heart's normal contraction might contribute to the development of or exacerbate heart failure. Conceptually and in practice cardiac dyssynchrony is complex. Recent studies have shown that atrio-biventricular pacing can improve cardiac synchrony in many patients and improve cardiac function, symptoms and exercise capacity, and reduce morbidity and mortality substantially. Randomized controlled trials, however, indicate that the severity of cardiac dyssynchrony, as conventionally measured, is a poor guide to treatment benefit and that correction of dyssynchrony accounts for only part of the benefit of atrio-biventricular pacing. Although some of the benefits of atrio-biventricular pacing might be mediated by cardiac resynchronization, much of the benefit could be mediated by mechanisms that are as yet unknown. Withholding atrio-biventricular pacing in patients who do not exhibit cardiac dyssynchrony on imaging but otherwise fulfil the entry criteria used in randomized controlled trials of this therapy could be unwise. Here, we examine the evidence that cardiac resynchronization is indeed the mechanism by which atrio-biventricular pacing exerts its effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245403     DOI: 10.1038/ncpcardio0794

Source DB:  PubMed          Journal:  Nat Clin Pract Cardiovasc Med        ISSN: 1743-4297


  6 in total

1.  Device therapy: Defibrillators-a shocking therapy for cardiomyopathy?

Authors:  John G F Cleland; Laszlo Buga
Journal:  Nat Rev Cardiol       Date:  2010-02       Impact factor: 32.419

Review 2.  How to improve outcomes: should we put more emphasis on programming and medical care and less on patient selection?

Authors:  Laszlo Buga
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

Review 3.  The determinants of clinical outcome and clinical response to CRT are not the same.

Authors:  John G F Cleland; Stefano Ghio
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

Review 4.  Cardiac resynchronization therapy is certainly cardiac therapy, but how much resynchronization and how much atrioventricular delay optimization?

Authors:  Andreas Kyriacou; Punam A Pabari; Darrel P Francis
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

5.  The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.

Authors:  John G F Cleland; Michael R Bristow; Nicholas Freemantle; Brian Olshansky; Daniel Gras; Leslie Saxon; Luigi Tavazzi; John Boehmer; Stefano Ghio; Arthur M Feldman; Jean-Claude Daubert; David de Mets
Journal:  Eur J Heart Fail       Date:  2022-05-22       Impact factor: 17.349

6.  The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial.

Authors:  Gerhard Wikstrom; Carina Blomström-Lundqvist; Bertil Andren; Stefan Lönnerholm; Per Blomström; Nick Freemantle; Thomas Remp; John G F Cleland
Journal:  Eur Heart J       Date:  2009-01-24       Impact factor: 29.983

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.